Besides, there were nine trials provide PFS data for postmenopausal women with HR+, HER2- advanced breast cancer, the pooled HR of PFS determined by the random-effect model (P = 0.004, I2 = 72%) was 0.71(95%CI: 0.60–0.85). This evidence concerns the gene ERBB2 and breast carcinoma.